NeuroSense Therapeutics (NRSN) Receivables - Other (2020 - 2025)
NeuroSense Therapeutics (NRSN) posted Receivables - Other of $565000.0 for Q4 2025, down 33.29% sequentially from $847000.0 in Q2 2025, and down 42.87% YoY from $989000.0 in Q4 2024.
NeuroSense Therapeutics (NRSN) Receivables - Other (2020 - 2025) Analysis & Trends
NeuroSense Therapeutics has reported Receivables - Other for 6 years, with the latest figure at $565000.0 in Q4 2025.
- Quarterly Receivables - Other fell 42.87% year-over-year to $565000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $565000.0 (down 42.87% YoY) and the FY2025 annual result came in at $565000.0, down 42.87% from the prior year.
- Receivables - Other slipped to $565000.0 in Q4 2025 per NRSN's latest filing, from $847000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $434.0 million in Q2 2023 and troughed at $14000.0 in Q2 2021.
- A 5-year average of $27.5 million and a median of $413500.0 in 2024 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2023 and 2024: Receivables - Other jumped 61286.14% in 2023, then slumped 99.91% in 2024.
- Over 5 years, Receivables - Other stood at $310000.0 in 2021, then retreated by 17.74% to $255000.0 in 2022, then declined by 7.45% to $236000.0 in 2023, then surged by 319.07% to $989000.0 in 2024, then tumbled by 42.87% to $565000.0 in 2025.
- According to Business Quant data, Receivables - Other over the past three periods registered $565000.0, $847000.0, and $989000.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 565,000.00 |
| Dec 31, 2025 | 565,000.00 |
| Jun 30, 2025 | 847,000.00 |
| Jun 30, 2025 | 847,000.00 |
| Dec 31, 2024 | 989,000.00 |
| Dec 31, 2024 | 989,000.00 |
| Sep 30, 2024 | 406,000.00 |
| Sep 30, 2024 | 406,000.00 |
| Jun 30, 2024 | 376,000.00 |
| Jun 30, 2024 | 376,000.00 |
| Mar 31, 2024 | 421,000.00 |
| Mar 31, 2024 | 421,000.00 |
| Dec 31, 2023 | 236,000.00 |
| Dec 31, 2023 | 236,000.00 |
| Sep 30, 2023 | 309,000.00 |
| Sep 30, 2023 | 309,000.00 |
| Jun 30, 2023 | 434.00 Mn |
| Jun 30, 2023 | 434.00 Mn |
| Mar 31, 2023 | 567,000.00 |
| Mar 31, 2023 | 567,000.00 |